REGNRegeneron PharmaceuticalsRunning, no new patients
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Melanoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 151 (final count)
- Started
- Sep 18, 2024
- Main results expected
- Nov 2, 2026
- Fully finished
- Dec 9, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR)
Measured over: Up to 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06190951 · record last updated 2026-02-10 · checked 2026-11-09 15:47 UTC